Rezolute, Inc. (RZLT) |
|
1.92 0.02 (1.03%)
|
03-31 16:00 |
|
Open: |
1.86 |
Pre. Close: |
1.9005 |
|
High:
|
1.97 |
Low:
|
1.55 |
|
Volume:
|
22,406 |
Market Cap:
|
78(M) |
|
|
|
Technical analysis |
as of: 2023-03-31 4:21:52 PM |
|
Overall:
|
 |
| Stoxline posted a NEUTRAL today, same as yesterday. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
| Target: |
Six months: 2.63  One year: 3.13 |
| Support: |
Support1: 1.55 Support2: 1.29 |
| Resistance: |
Resistance1: 2.25 Resistance2: 2.68 |
| Pivot: |
2.03 |
| Moving Average: |
MA(5): 1.95 MA(20): 2.13
MA(100): 2.03  MA(250): 2.57 |
| MACD: |
MACD(12,26): -0.2 Signal(9): -0.2 |
| Stochastic oscillator: |
%K(14,3): 28.7 %D(3): 21.6 |
| RSI: |
RSI(14): 42.1 |
| 52-week: |
High: 4 Low: 1.34 |
| Average Vol(K): |
3-Month: 28 (K) 10-Days: 38 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ RZLT ] has closed above bottom band by 28.0%. Bollinger Bands are 12.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
1.97 - 1.98 |
1.98 - 1.99 |
|
Low:
|
1.54 - 1.55 |
1.55 - 1.56 |
|
Close:
|
1.9 - 1.92 |
1.92 - 1.94 |
|
Company Description |
|
Rezolute, Inc., a clinical stage biopharmaceutical company, develops transformative therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, a selective and potent plasma kallikrein inhibitor, which is in Phase 1 clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California. |
Headline News |
Wed, 29 Mar 2023
Insiders who bought stock earlier this year lose -US$195k as Rezolute, Inc. (NASDAQ:RZLT) drops to US$68m - Simply Wall St
Thu, 23 Mar 2023
Rezolute KOL Event Highlights Significant Unmet Medical Need in ... - GlobeNewswire
Wed, 08 Mar 2023
Rezolute to Highlight RZ402 Phase 2 Clinical Program with Leading Clinical Expert - Marketscreener.com
Wed, 15 Feb 2023
GlycoMimetics stock falls after 11.8M stock offering (NASDAQ:GLYC) - Seeking Alpha
Fri, 10 Feb 2023
Rezolute Reports Second Quarter Fiscal 2023 Results and ... - GlobeNewswire
Thu, 02 Feb 2023
After losing 37% in the past year, Rezolute, Inc. (NASDAQ:RZLT) institutional owners must be relieved by the recent gain - Yahoo Eurosport UK
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Neutral |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
37 (M) |
| Shares Float |
26 (M) |
|
% Held by Insiders
|
21.6 (%) |
|
% Held by Institutions
|
70.2 (%) |
|
Shares Short
|
190 (K) |
|
Shares Short P.Month
|
218 (K) |
Stock Financials |
|
EPS
|
-3.02 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
4.3 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
-28.6 |
|
Return on Equity (ttm)
|
-49.4 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
-1.21 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-41 (M) |
|
Levered Free Cash Flow
|
-24 (M) |
Stock Valuations |
|
PE Ratio
|
-0.64 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0.44 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
-1.74 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
2020-10-12 |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
